## Mathieu C Tamby

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10973347/publications.pdf

Version: 2024-02-01

516710 752698 19 979 16 20 g-index citations h-index papers 20 20 20 1134 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The Role of Inflammation and Autoimmunity in the Pathophysiology of Pulmonary Arterial Hypertension. Clinical Reviews in Allergy and Immunology, 2013, 44, 31-38.	6.5	85
2	IgG from patients with pulmonary arterial hypertension and/or systemic sclerosis binds to vascular smooth muscle cells and induces cell contraction. Annals of the Rheumatic Diseases, 2012, 71, 596-605.	0.9	41
3	Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. European Respiratory Journal, 2012, 39, 1405-1414.	6.7	90
4	Proteomes of umbilical vein and microvascular endothelial cells reflect distinct biological properties and influence immune recognition. Proteomics, 2012, 12, 2547-2555.	2.2	28
5	Identification of new autoantibody specificities directed at proteins involved in the transforming growth factor $\hat{I}^2$ pathway in patients with systemic sclerosis. Arthritis Research and Therapy, 2011, 13, R74.	3.5	17
6	Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach. Arthritis Research and Therapy, 2011, 13, R107.	<b>3.</b> 5	44
7	Pathogenesis of giant cell arteritis: More than just an inflammatory condition?. Autoimmunity Reviews, 2010, 9, 635-645.	5.8	110
8	Identification of target antigens of antiendothelial cell antibodies in healthy individuals: A proteomic approach. Proteomics, 2008, 8, 1000-1008.	2.2	39
9	Identification of Target Antigens of Antifibroblast Antibodies in Pulmonary Arterial Hypertension. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1128-1134.	5.6	112
10	IgG from patients with systemic sclerosis bind to DNA antitopoisomerase 1 in normal human fibroblasts extracts. Biologics: Targets and Therapy, 2008, 2, 583.	3.2	6
11	Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis. Clinical Immunology, 2007, 123, 82-88.	3.2	9
12	Serum Eosinophil Cationic Protein: A Marker of Disease Activity in Churg-Strauss Syndrome. Annals of the New York Academy of Sciences, 2007, 1107, 392-399.	3.8	38
13	Antitopoisomerase 1 Antibodies in Systemic Sclerosis: How to Improve the Detection?. Annals of the New York Academy of Sciences, 2007, 1109, 221-228.	3.8	7
14	A Combined SDS-PAGE and Proteomics Approach to Identify Target Autoantigens in Healthy Individuals and Patients with Autoimmune Diseases. Annals of the New York Academy of Sciences, 2007, 1109, 538-549.	3.8	21
15	Anti-endothelial cell antibodies from patients with limited cutaneous systemic sclerosis bind to centromeric protein B (CENP-B). Clinical Immunology, 2006, 120, 212-219.	3.2	42
16	Analysis of autoantibody repertoires in small- and medium-sized vessels vasculitides. Evidence for specific perturbations in polyarteritis nodosa, microscopic polyangiitis, Churg–Strauss syndrome and Wegener's granulomatosis. Journal of Autoimmunity, 2005, 24, 169-179.	6.5	15
17	lgG reactivity with a 100-kDa tissue and endothelial cell antigen identified as topoisomerase 1 distinguishes between limited and diffuse systemic sclerosis patients. Clinical Immunology, 2004, 111, 241-251.	3.2	49
18	IgM and IgG autoantibodies from microscopic polyangiitis patients but not those with other small- and medium-sized vessel vasculitides recognize multiple endothelial cell antigens. Clinical Immunology, 2003, 109, 165-178.	3.2	34

## MATHIEU C TAMBY

#	Article	IF	CITATIONS
19	New insights into the pathogenesis of systemic sclerosis. Autoimmunity Reviews, 2003, 2, 152-157.	5.8	141